HPV Vaccine Research
The human papillomavirus (HPV) vaccine is highly effective at conferring protection against HPV and associated cervical cancers. Current practice calls for the vaccine to be administered in three doses; however, a reduced dosing regimen could save money and decrease the burden on patients.
To determine if a two-dose HPV vaccine provide equivalent protection, MSFHR is funding a long-term national study. The Quadrivalent HPV Vaccine Evaluation Study (QUEST) will follow more than 8,500 teenage girls recruited from BC, Alberta, Quebec, and the Maritimes, for up to 10 years. The study will assess risk factors, prevalence, and the level of protection provided by a two-dose vaccine compared to three doses.
QUEST builds on earlier HPV vaccine research funded by MSFHR. In 2006, the BC provincial health officer asked MSFHR to oversee research to determine the most cost-effective way to provide HPV immunity. The resulting study, led by researchers at the Child & Family Research Institute and the BC Centre for Disease Control, established the short-term effectiveness of a two-dose HPV vaccine. QUEST aims to determine if this protection is maintained over a longer term.